GeoVax Labs, Inc. Provides Clinical Stud... (erica and two in South America. Sites in...)

GeoVax Labs, Inc. Provides Clinical Studies Update

Date:8/5/2009

erica and two in South America. Sites in the United States include Emory University, Atlanta; Harvard Medical School, Boston; Vanderbilt University, Nashville; University of Rochester; Fred Hutchinson Cancer Research Center, Seattle; the San Francisco Department of Public Health; University of Alabama, Birmingham and sites at Columbia University, Union Square, and the Bronx in New York City. In South America, participants are to be enrolled in Peru at sites in Iquitos and Miraflores (Lima).

Therapeutic Clinical Trials - Planning for Phase 1

To help serve those people who are already infected with HIV, the Company is preparing for a Phase 1 therapeutic trial to start in early 2010. "The goal here is to reduce the need for anti-viral drugs. This initial trial will determine the safety and immunogenicity of the vaccine in patients with well controlled infections who started on drugs within six months of testing positive for HIV," stated McNally.

He continued, "You will recall that trials conducted using a simian immunodeficiency virus (SIV) prototype of the GeoVax HIV vaccine in SIV-infected primate animal models have held high promise that the GeoVax vaccine will be able to contribute to the control of HIV-1 in already infected humans. Our team is working hard to develop the clinical trial protocol and to assemble all the information required for an FDA submission seeking approval to move forward with the clinical trial. We plan to submit our package to the FDA in the very near future."

The initial therapeutic trial will be conducted locally in Atlanta. This first step will be a safety trial using intensive monitoring to verify the ultimate safety of the vaccine.

The Technology

GeoVax's unique two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV T cell and anti-HIV antibody immu
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. GeoVax Labs, Inc. Announces Resignation of Director
2. GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois
3. GeoVax to Exhibit at the 2009 BIO International Convention
4. GeoVax Labs, Inc. Announces First Quarter Financial Results
5. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
6. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
7. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
8. GeoVax to Present at the BIO CEO & Investor Conference 2009
9. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
10. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
11. GeoVax Presents Data at AIDS Vaccine 2008 Conference

Post Your Comments:

GeoVax Labs, Inc. Provides Clinical Stud...(erica and two in South America. Sites in...)